# Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

> **NCT02802423** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **BioLite, Inc.** · enrollment: 44 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** BLEX 404 Oral Liquid

## Key facts

- **NCT ID:** NCT02802423
- **Lead sponsor:** BioLite, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-01
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-08-28
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02802423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02802423, "Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02802423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*